These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 38534508)
21. Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Cao J; Gong L; Guo DC; Mietzsch U; Kuang SQ; Kwartler CS; Safi H; Estrera A; Gambello MJ; Milewicz DM Hum Mol Genet; 2010 May; 19(10):1908-20. PubMed ID: 20159776 [TBL] [Abstract][Full Text] [Related]
22. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. Mi R; Ma J; Zhang D; Li L; Zhang H J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex. Lu Y; Zhang EY; Liu J; Yu JJ Orphanet J Rare Dis; 2020 Aug; 15(1):209. PubMed ID: 32807195 [TBL] [Abstract][Full Text] [Related]
29. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
30. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies. McEneaney LJ; Tee AR Adv Genet; 2019; 103():91-118. PubMed ID: 30904097 [TBL] [Abstract][Full Text] [Related]
31. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366 [TBL] [Abstract][Full Text] [Related]
33. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Kenerson H; Dundon TA; Yeung RS Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109 [TBL] [Abstract][Full Text] [Related]
34. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109 [TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. Messina MP; Rauktys A; Lee L; Dabora SL BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349 [TBL] [Abstract][Full Text] [Related]
36. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database. Boggarapu S; Roberds SL; Nakagawa J; Beresford E Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799 [TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis. Kim WS Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518 [TBL] [Abstract][Full Text] [Related]